S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Cellectis Stock Forecast, Price & News

-1.12 (-5.80 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $18.19
50-Day Range
MA: $26.76
52-Week Range
Now: $18.19
Volume775,437 shs
Average Volume454,703 shs
Market Capitalization$772.82 million
P/E RatioN/A
Dividend YieldN/A
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.
Cellectis logo


Why Airbnb Stock Dropped Today - Nasdaq
March 6, 2021 |  nasdaq.com
Cellectis: Q4 Earnings Insights - Yahoo Finance
March 5, 2021 |  finance.yahoo.com
Cellectis: Q4 Earnings Insights
March 4, 2021 |  finance.yahoo.com
Cellectis: Q4 Earnings Insights - Benzinga
March 4, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:CLLS
Year FoundedN/A



Sales & Book Value

Annual Sales$22.99 million
Book Value$8.37 per share


Net Income$-102,090,000.00
Net Margins-110.52%


Market Cap$772.82 million
Next Earnings Date5/5/2021 (Estimated)


Overall MarketRank

1.26 out of 5 stars

Medical Sector

853rd out of 1,969 stocks

Biological Products, Except Diagnostic Industry

118th out of 177 stocks

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-1.12 (-5.80 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Cellectis (NASDAQ:CLLS) Frequently Asked Questions

Is Cellectis a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cellectis stock.
View analyst ratings for Cellectis
or view top-rated stocks.

What stocks does MarketBeat like better than Cellectis?

Wall Street analysts have given Cellectis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cellectis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cellectis?

Cellectis saw a decrease in short interest in the month of January. As of January 29th, there was short interest totaling 438,700 shares, a decrease of 28.6% from the January 14th total of 614,200 shares. Based on an average trading volume of 425,000 shares, the days-to-cover ratio is currently 1.0 days. Approximately 1.0% of the company's stock are short sold.
View Cellectis' Short Interest

When is Cellectis' next earnings date?

Cellectis is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Cellectis

How were Cellectis' earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) issued its earnings results on Thursday, March, 4th. The biotechnology company reported ($0.95) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.01) by $0.06. Cellectis had a negative net margin of 110.52% and a negative trailing twelve-month return on equity of 23.56%.
View Cellectis' earnings history

How has Cellectis' stock been impacted by COVID-19?

Cellectis' stock was trading at $11.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CLLS stock has increased by 59.1% and is now trading at $18.19.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CLLS?

4 equities research analysts have issued twelve-month price targets for Cellectis' shares. Their forecasts range from $21.00 to $33.00. On average, they expect Cellectis' share price to reach $28.67 in the next year. This suggests a possible upside of 57.6% from the stock's current price.
View analysts' price targets for Cellectis
or view top-rated stocks among Wall Street analysts.

Who are Cellectis' key executives?

Cellectis' management team includes the following people:
  • Dr. André Choulika, Co-Founder, CEO & Director (Age 56, Pay $1M)
  • Dr. David J. D. Sourdive, Co-Founder, Exec. VP of Strategic Initiatives & Director (Age 54, Pay $452.66k)
  • Mr. Eric Dutang, Chief Financial Officer (Age 47)
  • Mr. Jean Charles Epinat, Chief Technological Officer
  • Mr. Stephan Reynier, Chief Regulatory & Compliance Officer (Age 52)
  • Ms. Marie-Bleuenn Terrier, Gen. Counsel (Age 39)
  • Ms. Jennifer Moore, Sr. VP of PR
  • Ms. Kyung Nam-Wortman, Exec. VP & Chief HR Officer
  • Dr. Philippe Duchateau Ph.D., Chief Scientific Officer (Age 58)
  • Simon Harnest, Sr. VP of Corp. Strategy & Fin.

What is André Choulika's approval rating as Cellectis' CEO?

4 employees have rated Cellectis CEO André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among Cellectis' employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Cellectis' key competitors?

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).

When did Cellectis IPO?

(CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Who are Cellectis' major shareholders?

Cellectis' stock is owned by many different institutional and retail investors. Top institutional investors include Credit Suisse AG (2.83%), Sumitomo Mitsui Trust Holdings Inc. (1.82%), Nikko Asset Management Americas Inc. (1.82%), Morgan Stanley (0.72%), BlackRock Inc. (0.37%) and Kennedy Capital Management Inc. (0.28%).

Which major investors are selling Cellectis stock?

CLLS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Eqis Capital Management Inc., Aperio Group LLC, Citigroup Inc., Princeton Capital Management LLC, Wells Fargo & Company MN, and Kennedy Capital Management Inc..

Which major investors are buying Cellectis stock?

CLLS stock was purchased by a variety of institutional investors in the last quarter, including Credit Suisse AG, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Vontobel Holding Ltd., Capital Impact Advisors LLC, KBC Group NV, OneAscent Wealth Management LLC, and Exchange Traded Concepts LLC.

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $18.19.

How much money does Cellectis make?

Cellectis has a market capitalization of $772.82 million and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis.

How many employees does Cellectis have?

Cellectis employs 253 workers across the globe.

What is Cellectis' official website?

The official website for Cellectis is www.cellectis.com.

Where are Cellectis' headquarters?

Cellectis is headquartered at 8 RUE DE LA CROIX JARRY, PARIS I0, 75013.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]

This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.